Europital board forewarns that clinical deficits to slow biotech development in 2021 February 11, 2021 Ghent (Belgium), 08 February 2021: The newly formed Scientific Advisory Board (SAB) of Europital – a globally-focused, full-service CRO serving small and mid-tier innovators – forewarns that a clinical knowledge deficit amongst smaller biotechs will potentially slow trials in 2021. The Europital SAB, comprises a group of clinical KOLs and specialized industry experts and has been created to address many of the more complex targets and biologies that now proliferate in the drug discovery pipeline. “The drug discovery pipeline is increasingly made up of smaller and more nimble innovators with limited clinical experience in-house. Yet, with many of the low hanging fruit already having been developed, molecules and biologies are becoming ever more complex. The challenge for small and medium pharma and biotechs is how to access appropriate high-quality clinical knowledge – and this clinical deficit over the next few years is set to be a critical factor in any candidates advancement,” commented Dr. Mohamed El Malt, Chief Medical Officer of Europital.